OBJECTIVES: To inform future economic evaluations of human papilloma virus (HPV) vaccination, a systematic literature review was conducted to identify recent evidence of health state utilities for HPV-related diseases.

METHODS: MEDLINE, EMBASE, Cochrane CENTRAL and PsycInfo were systematically searched for utility studies on HPV related diseases and Head and Neck Cancer (HNC) published in the last 10 years in English that met the pre-set eligibility criteria. Only studies that reported original health state utility data were included.

RESULTS: Twenty-seven studies were identified and mean utility scores were summarised. Utilities were elicited using EQ-5D, visual analog scale (VAS), standard gamble, time trade-off, SF-6D and HUI 3. According to EQ-5D, health state utilities ranged from 0.75 to 0.87 for genital warts in women, 0.81 to 0.89 for genital warts in men 0.77 to 0.85 for cervical intraepithelial neoplasia (CIN) grade 1, 0.58 to 0.81 for CIN 2-3, 0.15 to 0.87 for cervical cancer, 0.72 to 0.74 for vulvar intraepithelial neoplasia (VIN) grade 2-3, 0.58 to 0.69 for HPV-related HNC and 0.62 to 0.84 for HPV-unrelated HNC. EQ-5D value sets from seven different countries were applied (Argentina, Canada, Chile, Japan, Thailand, the UK and USA). VAS utility scores ranged from 0.62 to 0.78 for genital warts in women, 0.69 to 0.79 for genital warts in men, 0.61 to 0.78 for CIN 1, 0.60 to 0.77 for CIN 2-3, 0.18 to 0.59 for cervical cancer, 0.62 to 0.66 for VIN 2-3, 0.75 for recurrent respiratory papillomatosis and 0.48 to 0.85 for HPV-unrelated HNC.

CONCLUSIONS: We identified a large number of recent studies that reported health state utilities for HPV-related diseases and HNC, which could be used in economic evaluations. However, variation was observed in the utility elicitation method used and value sets applied.